An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...

We have made great strides in the medical community, with people having access to life-saving physical drugs as well as ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with ma ...

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...